DPYSL2 and breast carcinoma: It has been reported that increased levels of nuclear phosphorylated DPYSL2 correlate with poor prognosis in patients with NSCLC (Oliemuller et al., 2013), but has no association with clinical outcome, tumor size, lymph node metastasis, and histological grade in patients with breast cancer (Shimada et al., 2014).